Co-Diagnostics (CODX) Stock Price

Co-Diagnostics Price

NASDAQ·CLOSED
2.28USD-0.08 (-3.45 %)
Market closed

Revenue has compounded at 94.1% per year over the past 9 years to 3.92 M USD. Co-Diagnostics's net margin stands at -961.4%, down from 57.0% several years earlier. Analysts set a median price target of 30.60 USD, implying 1,242.1% above the current price. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 77% above its 52-week low.

Co-Diagnostics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Co-Diagnostics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Co-Diagnostics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Co-Diagnostics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Co-Diagnostics Stock Price History
DateCo-Diagnostics Price
7/22/20262.28 USD
7/21/20262.36 USD
7/20/20262.44 USD
7/17/20262.46 USD
7/16/20262.48 USD
7/15/20262.49 USD
7/14/20262.57 USD
7/13/20262.61 USD
7/10/20262.61 USD
7/9/20262.64 USD
7/8/20262.60 USD
7/7/20262.71 USD
7/6/20262.95 USD
7/2/20262.99 USD
7/1/20263.08 USD
6/30/20263.10 USD
6/29/20262.98 USD
6/26/20263.06 USD
6/25/20263.05 USD
6/24/20263.57 USD
6/23/20263.23 USD
6/22/20263.21 USD
6/18/20263.37 USD
6/17/20263.33 USD
6/16/20263.84 USD
6/15/20263.78 USD
6/12/20264.29 USD
6/11/20264.70 USD
6/10/20264.88 USD
6/9/20264.50 USD
6/8/20265.05 USD
6/5/20265.63 USD
6/4/20265.76 USD
6/3/20265.17 USD
6/2/20266.22 USD
6/1/20266.20 USD
5/29/20268.53 USD
5/28/202611.19 USD
5/27/20267.30 USD
5/26/20269.11 USD
5/22/20265.07 USD
5/21/20263.71 USD
5/20/20262.39 USD
5/19/20261.97 USD
5/18/20261.37 USD
5/15/20261.28 USD
5/14/20261.63 USD
5/13/20261.60 USD
5/12/20261.72 USD
5/11/20261.90 USD
5/8/20262.53 USD
5/7/20261.93 USD
5/6/20261.64 USD
5/5/20261.59 USD
5/4/20261.57 USD
5/1/20261.55 USD
4/30/20261.55 USD
4/29/20261.53 USD
4/28/20261.63 USD
4/27/20261.65 USD
4/24/20261.67 USD
4/23/20261.71 USD
4/22/20261.69 USD
4/21/20261.64 USD
4/20/20261.67 USD
4/17/20261.56 USD
4/16/20261.46 USD
4/15/20261.42 USD
4/14/20261.38 USD
4/13/20261.45 USD
4/10/20261.37 USD
4/9/20261.44 USD
4/8/20261.39 USD
4/7/20261.42 USD
4/6/20261.53 USD
4/2/20261.54 USD
4/1/20261.62 USD
3/31/20261.86 USD
3/30/20261.70 USD
3/27/20261.75 USD
3/26/20262.02 USD
3/25/20261.97 USD
3/24/20262.27 USD
3/23/20262.28 USD
3/20/20262.59 USD
3/19/20262.65 USD
3/18/20262.31 USD
3/17/20262.29 USD
3/16/20262.50 USD
3/13/20262.80 USD
3/12/20262.63 USD
3/11/20263.24 USD
3/10/20264.40 USD
3/9/20262.18 USD
3/6/20262.11 USD
3/5/20262.33 USD
3/4/20262.33 USD
3/3/20262.23 USD
3/2/20262.30 USD
2/27/20262.30 USD
2/26/20262.32 USD
2/25/20262.20 USD
2/24/20262.33 USD
2/23/20262.32 USD
2/20/20262.45 USD
2/19/20262.45 USD
2/18/20262.52 USD
2/17/20262.49 USD
2/13/20262.49 USD
2/12/20262.35 USD
2/11/20262.35 USD
2/10/20262.36 USD
2/9/20262.22 USD
2/6/20262.33 USD
2/5/20262.35 USD
2/4/20262.35 USD
2/3/20262.35 USD
2/2/20262.42 USD
1/30/20262.38 USD
1/29/20262.72 USD
1/28/20262.81 USD
1/27/20262.82 USD
1/26/20263.00 USD
1/23/20262.99 USD
1/22/20262.99 USD
1/21/20262.94 USD
1/20/20263.00 USD
1/16/20262.83 USD
1/15/20262.92 USD
1/14/20263.35 USD
1/13/20262.36 USD
1/12/20262.36 USD
1/9/20262.44 USD
1/8/20262.42 USD
1/7/20262.38 USD
1/6/20262.25 USD
1/5/20262.27 USD
1/2/20262.19 USD
12/31/20252.00 USD
12/30/20252.14 USD
12/29/20252.71 USD
12/26/20252.78 USD
12/24/20252.85 USD
12/23/20252.90 USD
12/22/20253.04 USD
12/19/20253.13 USD
12/18/20253.27 USD
12/17/20253.10 USD
12/16/20252.91 USD
12/15/20253.20 USD
12/12/20254.04 USD
12/11/20254.12 USD
12/10/20254.24 USD
12/9/20254.30 USD
12/8/20254.11 USD
12/5/20254.44 USD
12/4/20254.58 USD
12/3/20254.23 USD
12/2/20254.14 USD
12/1/20254.27 USD
11/28/20254.39 USD
11/26/20254.42 USD
11/25/20253.85 USD
11/24/20253.95 USD
11/21/20254.14 USD
11/20/20253.81 USD
11/19/20254.05 USD
11/18/20254.25 USD
11/17/20253.74 USD
11/14/20253.92 USD
11/13/20254.40 USD
11/12/20254.69 USD
11/11/20254.66 USD
11/10/20254.62 USD
11/7/20254.81 USD
11/6/20254.66 USD
11/5/20254.64 USD
11/4/20254.49 USD
11/3/20254.78 USD
10/31/20255.45 USD
10/30/20255.54 USD
10/29/20255.85 USD
10/28/20256.75 USD
10/27/20256.75 USD
10/24/20251.88 USD
10/23/20251.78 USD
10/22/20251.71 USD
10/21/20251.82 USD
10/20/20251.85 USD
10/17/20251.74 USD
10/16/20251.87 USD
10/15/20252.06 USD
10/14/20251.99 USD
10/13/20252.06 USD
10/10/20252.03 USD
10/9/20252.30 USD
10/8/20252.11 USD
10/7/20252.01 USD
10/6/20252.04 USD
10/3/20252.06 USD
10/2/20251.90 USD
10/1/20251.89 USD
9/30/20251.84 USD
9/29/20251.98 USD
9/26/20252.05 USD
9/25/20252.01 USD
9/24/20252.22 USD
9/23/20252.14 USD
9/22/20252.24 USD
9/19/20252.35 USD
9/18/20252.30 USD
9/17/20252.23 USD
9/16/20253.42 USD
9/15/20251.89 USD
9/12/20251.83 USD
9/11/20251.84 USD
9/10/20251.64 USD
9/9/20251.68 USD
9/8/20251.66 USD
9/5/20251.66 USD
9/4/20251.65 USD
9/3/20251.76 USD
9/2/20251.71 USD
8/29/20251.77 USD
8/28/20251.79 USD
8/27/20251.75 USD
8/26/20251.67 USD
8/25/20251.70 USD
8/22/20251.71 USD
8/21/20251.64 USD
8/20/20251.51 USD
8/19/20251.55 USD
8/18/20251.71 USD
8/15/20251.57 USD
8/14/20251.42 USD
8/13/20251.41 USD
8/12/20251.36 USD
8/11/20251.36 USD
8/8/20251.36 USD
8/7/20251.32 USD
8/6/20251.35 USD
8/5/20251.34 USD
8/4/20251.38 USD
8/1/20251.33 USD
7/31/20251.39 USD
7/30/20251.38 USD
7/29/20251.40 USD
7/28/20251.49 USD
7/25/20251.50 USD
Access this data via the Eulerpool API
Get Free API Key

Co-Diagnostics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
34.22 M USD
-11.59 M USD
-14.24 M USD
Jan 1, 2023
6.81 M USD
-42.71 M USD
-35.33 M USD
Jan 1, 2024
3.92 M USD
-40.08 M USD
-37.64 M USD
Jan 1, 2025 (e)
494,190.00 USD
-31.56 M USD
-21.66 M USD
Jan 1, 2026 (e)
587,520.00 USD
-33.40 M USD
-12.53 M USD
Jan 1, 2027 (e)
17.53 M USD
-38.48 M USD
-12.38 M USD
Jan 1, 2028 (e)
215.92 M USD
113.54 M USD
0.00 USD
Jan 1, 2029 (e)
139.32 M USD
22.73 M USD
6.81 M USD

Co-Diagnostics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 24, 2026, 8:15 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2016201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
––––74.0097.0034.006.003.00––17.00215.00139.00215.00257.00
–––––31.08-64.95-82.35-50.00–––1,164.71-35.3554.6819.53
––––77.0388.6682.3533.3366.67––66.6766.6766.6766.6766.67
2.002.002.002.0057.0086.0028.002.002.002.002.0011.33143.3392.67143.33171.33
-1.00-4.00-6.00-5.0041.0046.00-11.00-42.00-40.00-31.00-33.00-38.00113.0022.0067.00–
––––55.4147.42-32.35-700.00-1,333.33––-223.5352.5615.8331.16–
-1.00-6.00-6.00-6.0042.0036.00-14.00-35.00-37.00-21.00-12.00-12.00–6.0020.0025.00
-50.00500.00––-800.00-14.29-138.89150.005.71-43.24-42.86–––233.3325.00
0.330.370.420.560.931.001.050.981.011.011.011.011.011.011.011.01
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Co-Diagnostics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Co-Diagnostics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Co-Diagnostics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Co-Diagnostics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Co-Diagnostics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Co-Diagnostics stock margins

The Co-Diagnostics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Co-Diagnostics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Co-Diagnostics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
77.75 %
55.92 %
56.98 %
Jan 1, 2021
88.17 %
47.21 %
37.45 %
Jan 1, 2022
83.99 %
-33.87 %
-41.61 %
Jan 1, 2023
38.57 %
-626.93 %
-518.69 %
Jan 1, 2024
74.48 %
-1,023.74 %
-961.36 %
Jan 1, 2025 (e)
74.48 %
-6,386.17 %
-4,382.48 %
Jan 1, 2026 (e)
74.48 %
-5,685.68 %
-2,132.79 %
Jan 1, 2027 (e)
74.48 %
-219.49 %
-70.60 %

Co-Diagnostics Stock Revenue, EBIT, Earnings per Share

The Co-Diagnostics earnings per share therefore indicates how much revenue Co-Diagnostics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
2,396.34 USD
1,340.08 USD
1,365.48 USD
Jan 1, 2021
2,946.42 USD
1,390.89 USD
1,103.44 USD
Jan 1, 2022
978.46 USD
-331.40 USD
-407.17 USD
Jan 1, 2023
208.94 USD
-1,309.87 USD
-1,083.72 USD
Jan 1, 2024
116.17 USD
-1,189.24 USD
-1,116.77 USD
Jan 1, 2025 (e)
14.66 USD
-936.40 USD
-642.60 USD
Jan 1, 2026 (e)
17.43 USD
-991.13 USD
-371.79 USD
Jan 1, 2027 (e)
520.13 USD
-1,141.65 USD
-367.20 USD

Co-Diagnostics business model & stock analysis

Co-Diagnostics Segments

Co-Diagnostics Revenue by Segment

  • Max

Grant Revenue
Product Revenue
Details
Date
Grant Revenue
Product Revenue
Jan 1, 2023
5.82 M USD
991,473.00 USD
Jan 1, 2024
3.15 M USD
770,048.00 USD

Co-Diagnostics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Co-Diagnostics historical P/E ratio, EBIT multiple, and P/S ratio

Co-Diagnostics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Co-Diagnostics shares outstanding

The number of shares of Co-Diagnostics was 33,703.33 in 2025. This indicates how many shares Co-Diagnostics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
31,110.00 Stocks
Jan 1, 2021
33,223.33 Stocks
Jan 1, 2022
34,973.33 Stocks
Jan 1, 2023
32,603.33 Stocks
Jan 1, 2024
33,703.33 Stocks
Jan 1, 2025 (e)
33,703.33 Stocks
Jan 1, 2026 (e)
33,703.33 Stocks
Jan 1, 2027 (e)
33,703.33 Stocks

Co-Diagnostics stock splits

In Co-Diagnostics's history, there have been no stock splits.

Current Co-Diagnostics forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy0.00 % (0)
Hold57.14 % (4)
Sell42.86 % (3)
12M Price Target
30.60
Last Price
2.21
Currency
USD
12M Return Potential
1,284.62 %
LTM Return
0 %

Co-Diagnostics Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/12/2026-3.06USD169,830.00USD2026 Q2
5/14/2026-3.83USD166,770.00USD2026 Q1
5/6/2026-3.83USD166,770.00USD2026 Q1
3/19/2026-3.67USD128,520.00USD2025 Q4
11/13/2025-0.16USD153,000.00USD2025 Q3
8/14/2025-0.63USD153,000.00USD2025 Q2
11/7/2024-0.34USD382,500.00USD2024 Q3
5/9/2024-0.21USD3.16 MUSD2024 Q1
3/14/2024-0.20USD3.67 MUSD2023 Q4
11/8/2023-0.15USD6.34 MUSD2023 Q3

EESG©

Eulerpool ESG Scorecard© for the Co-Diagnostics stock

29/100
34
Environment
8
Social
44
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Co-Diagnostics shareholder structure

% Name
6.29384%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
6.21660%
Orca Capital GmbH
Orca Capital GmbH
3.89556%
Private Advisory Group LLC
Private Advisory Group LLC
2.84156%
Egan (Dwight H.)
Egan (Dwight H.)
2.40767%
Renaissance Technologies LLC
Renaissance Technologies LLC
2.29611%
Abbott (Richard David)
Abbott (Richard David)
...

Co-Diagnostics Executives and Management Board

DE

Mr. Dwight Egan

(71)

Chairman of the Board, President, Chief Executive Officer · since 2013

Compensation716,917.00 USD
BB

Mr. Brian Brown

(49)

Chief Financial Officer, Company Secretary

Compensation578,083.00 USD
RA

Mr. Richard Abbott

(53)

President

Compensation424,866.00 USD
ED

Dr. Eugene Durenard

(55)

Independent Director

Compensation222,100.00 USD
EM

Mr. Edward Murphy

(60)

Independent Director

Compensation222,100.00 USD

Co-Diagnostics Supply Chain

Co-Diagnostics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
4 companies
#Name1M3M6M1Y2YTrend
1
American Bio Medica
0.53
0.68
0.82
0.53
0.84
2
PolarityTE
0.74
0.62
0.76
0.63
0.79
#Name1M3M6M1Y2YTrend
1
Krebs Biochemicals & Inds
Supplier
0.79
-0.18
0.51
-0.09
-0.67
2
Walgreens Boots Alliance
0.18
0.61
0.64
0.42
-0.43

Frequently asked questions about Co-Diagnostics

Analysts currently set an average price target of 30.60 USD for the Co-Diagnostics stock (median: 30.60 USD), implying +1,284.6 % versus the latest price. The consensus is based on 7 analyst ratings.

Co-Diagnostics Analyst Price Targets 2026

All fundamentals and in-depth analysis of Co-Diagnostics

Our stock analysis for Co-Diagnostics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Co-Diagnostics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Co-Diagnostics Stock
Co-Diagnostics Revenue→
Co-Diagnostics Stock
Co-Diagnostics Net Income→
Co-Diagnostics Stock
Co-Diagnostics P/E→
Co-Diagnostics Stock
Co-Diagnostics P/S→
Co-Diagnostics Stock
Co-Diagnostics EBIT→
Co-Diagnostics Stock
Co-Diagnostics Dividend→
Co-Diagnostics Stock
Co-Diagnostics Directors Dealings→
Co-Diagnostics Stock
Co-Diagnostics Stocks→
Co-Diagnostics Stock
Co-Diagnostics Market capitalization→
Co-Diagnostics Stock
Co-Diagnostics Debt→
Co-Diagnostics Stock
Co-Diagnostics Liabilities→
Co-Diagnostics Stock
Co-Diagnostics Equity→
Co-Diagnostics Stock
Co-Diagnostics AAQS→
Co-Diagnostics Stock
Co-Diagnostics Employees→
Co-Diagnostics Stock
Co-Diagnostics ROE→
Co-Diagnostics Stock
Co-Diagnostics ROA→
Co-Diagnostics Stock
Co-Diagnostics ROCE→
Co-Diagnostics Stock
Co-Diagnostics News→
Co-Diagnostics Stock
Co-Diagnostics Analyst Price Targets→

Health Stocks

CochlearCNS PharmaceuticalsCocrystal PharmaCNBX PharmaceuticalsCoded Growth Innovation CenterCMG Pharmaceutical CoCodelab Capital ASCM HospitalarCodexisClover Health InvestmentsCoDonClover BiopharmaceuticalsAll Stocks A–Z →